News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) Announces Presentation at the Deutsche Bank (DB) 2012 dbAccess BioFEST



11/28/2012 9:12:05 AM

TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:




Manisha Narasimhan, Ph.D.

Peter Dworkin

Investor Relations

Corporate Communications

914-847-5126

914.847.7640

manisha.narasimhan@regeneron.com

peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES